AzurRx BioPharma, Inc., a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, issued the following letter to its shareholders and the investment community from James Sapirstein, President and Chief Executive Officer.
October 7, 2020
· 8 min read